Description:

GOG-0240 Cycle Dose Drug Form (Form D2R) Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer NCT00803062 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4580B20A-FA66-2748-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4580B20A-FA66-2748-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 8/27/12
  2. 1/8/15
  3. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Cycle Dose Drug Form (D2R) Cervical Cancer (NCT00803062)

No Instruction available.

  1. StudyEvent: GOG-0240 Cycle Dose Drug Form (Form D2R)
    1. No Instruction available.
Header Module
Treatment Cycle And Modification
Cycle Delayed?
days
Cycle delayed reason
Were there any dose modifications or additions/omissions to protocol treatment (1=Yes, planned; 2 =Yes, unplanned; 3=No)
Kg
m2
Performance status (Zubrod)
Pretreatment Hematology And Chemistry Values
g/dL
1000/uL
1000/uL
1000/uL
seconds
mg/dL
mg/dL

Similar models